Synergy of dual pathway inhibition in chronic cardiovascular disease: lessons from the COMPASS trial
M Coppens, JI Weitz, JWA Eikelboom - Circulation research, 2019 - Am Heart Assoc
Although acetylsalicylic acid is of proven benefit for secondary prevention in patients with
cardiovascular disease, the risk of recurrent ischemic events remains high. Intensification of …
cardiovascular disease, the risk of recurrent ischemic events remains high. Intensification of …
Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease
M Coppens, JI Weitz… - Circulation research, 2019 - pubmed.ncbi.nlm.nih.gov
Although acetylsalicylic acid is of proven benefit for secondary prevention in patients with
cardiovascular disease, the risk of recurrent ischemic events remains high. Intensification of …
cardiovascular disease, the risk of recurrent ischemic events remains high. Intensification of …
[引用][C] Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease
M Coppens, JI Weitz, JWA Eikelboom - Circulation Research, 2019 - elibrary.ru
Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease.
M Coppens, JI Weitz, JWA Eikelboom - Circulation Research, 2019 - europepmc.org
Although acetylsalicylic acid is of proven benefit for secondary prevention in patients with
cardiovascular disease, the risk of recurrent ischemic events remains high. Intensification of …
cardiovascular disease, the risk of recurrent ischemic events remains high. Intensification of …
Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease
M Coppens, JI Weitz… - Circulation …, 2019 - researchinformation.amsterdamumc …
Although acetylsalicylic acid is of proven benefit for secondary prevention in patients with
cardiovascular disease, the risk of recurrent ischemic events remains high. Intensification of …
cardiovascular disease, the risk of recurrent ischemic events remains high. Intensification of …